How much does Mobotinib cost in China?

Mobocertinib (Mobocertinib) is a third-generation tyrosine kinase inhibitor (TKI) developed by Japan's Takeda Pharmaceutical Co., Ltd. The drug is mainly used to treat EGFR (epidermal growth factor receptor) exon 20 insertion mutations in patients with non-small cell lung cancer (NSCLC). This type of mutation is often resistant to traditional EGFR-TKI drugs, and mobosetinib offers a new and effective treatment by irreversibly binding to and inhibiting the tyrosine kinase activity of these mutants.

Mobotinib has demonstrated significant efficacy in clinical trials, particularly in extending progression-free survival and improving objective response rates. In 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to mobotinib (mobosetinib) for the treatment of patients with non-small cell lung cancer with EGFRexon 20 insertion mutations. This drug provides a new treatment option for patients who have failed to respond to traditional treatment options, greatly improving their quality of life and prognosis.

In China, Mobotinib (Mobosetinib) is already on the market, but has not yet been included in the National Reimbursement Directory. This means patients need to pay for the drug out of pocket. Nonetheless, the introduction of this drug provides a new treatment option for non-small cell lung cancer patients with domestic EGFRexon20 insertion mutations. Patients can obtain detailed information and purchase channels for mobosetinib by consulting the oncology department or pharmacy of their local hospital.

Since Mobotinib (Mobosetinib) has not been included in the medical insurance, patients need to bear the cost of the drug themselves. In China, the price of Mobotinib (Mobosetinib) is relatively high, and the monthly treatment cost is about RMB 7 to 8,000. This is a considerable financial burden for most patients. Therefore, before purchasing, patients should fully understand the price of the drug and consider their financial affordability.